Insider Selling: Loxo Oncology (NASDAQ:LOXO) Insider Sells 3,082 Shares of Stock

Loxo Oncology (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of the stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $131.41, for a total value of $405,005.62. Following the sale, the insider now owns 1,541 shares in the company, valued at approximately $202,502.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Naarden Jacob Van also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Tuesday, February 13th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $96.34, for a total value of $296,919.88.
  • On Wednesday, January 17th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $88.21, for a total value of $271,863.22.
  • On Friday, December 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $81.19, for a total value of $250,227.58.

LOXO traded down $2.33 during trading on Friday, reaching $110.85. The stock had a trading volume of 276,035 shares, compared to its average volume of 458,223. The stock has a market cap of $3,329.27, a PE ratio of -20.88 and a beta of 2.32. Loxo Oncology has a one year low of $42.11 and a one year high of $135.74.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million during the quarter. equities research analysts predict that Loxo Oncology will post 0.3 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LOXO. Sands Capital Management LLC bought a new position in Loxo Oncology in the fourth quarter valued at $191,266,000. OppenheimerFunds Inc. grew its stake in shares of Loxo Oncology by 62.8% during the fourth quarter. OppenheimerFunds Inc. now owns 1,061,111 shares of the biopharmaceutical company’s stock valued at $89,324,000 after buying an additional 409,209 shares during the last quarter. Driehaus Capital Management LLC grew its stake in shares of Loxo Oncology by 40.3% during the fourth quarter. Driehaus Capital Management LLC now owns 574,495 shares of the biopharmaceutical company’s stock valued at $48,361,000 after buying an additional 164,959 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Loxo Oncology by 27.3% during the fourth quarter. Franklin Resources Inc. now owns 494,101 shares of the biopharmaceutical company’s stock valued at $41,594,000 after buying an additional 106,001 shares during the last quarter. Finally, California Public Employees Retirement System bought a new position in shares of Loxo Oncology during the fourth quarter valued at about $4,249,000.

A number of equities research analysts recently issued reports on LOXO shares. Stifel Nicolaus reiterated a “buy” rating and issued a $135.00 price objective on shares of Loxo Oncology in a research report on Friday, March 2nd. Cann started coverage on Loxo Oncology in a research report on Wednesday, February 21st. They issued an “outperform” rating and a $132.00 price objective on the stock. BidaskClub upgraded Loxo Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Citigroup reiterated a “buy” rating and issued a $151.00 price objective (up previously from $108.00) on shares of Loxo Oncology in a research report on Monday, March 5th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $124.44.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/naarden-jacob-van-sells-3082-shares-of-loxo-oncology-inc-loxo-stock-2.html.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply